

Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation'

<https://marketpublishers.com/r/G646DE368B1EN.html>

Date: February 2015

Pages: 280

Price: US\$ 3,400.00 (Single User License)

ID: G646DE368B1EN

Abstracts

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages. This report is presented as follows:

By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)

By Geography (Global, USA)

By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)

By Sub-market (Generics, Women's Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

Up-to-date company financials, sales & revenue figures

Revenue and market forecasts

Business model strategies for drug delivery, pharmaceutical and biotechnology companies

Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market

Technologies driving the market (e.g., chemical enhancers, microneedles)

Top fastest growing market segments and emerging opportunities

Top pharmaceutical companies within the market

Comprehensive product portfolios, R&D activity and pipeline products

M&A activity and future strategies of top companies

High demand and unmet need enhances the market

Challenges of the transdermal drug delivery market

Who should read this report?

Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine

Industry professionals and business strategists will discover key information to propel their policies

Investors will gain inside information to dominant players in the industry and future forecasts

Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:

Strong, competitive players

Pooling their resources for specific growth and therapeutic areas

Investing strategically in R&D

Have a history of strategic M&A activity

This detailed report is supported with 320 figures and tables over 280 pages and profiles the main pharmacos in the transdermal drug delivery market.

Benefits of Investing in our Cutting-Edge Reports:

Clients receive complementary content* with mid-level and enterprise wide licences

Post-sale complementary consultation with senior expert analyst is included

Use of tables and figures in your own reports and presentations is permitted

Each report provides straight-talking strategic analysis & sector intelligence

All reports are updated each quarter to give you the most up-to-date information

WE WANT TO MAXIMIZE YOUR BUSINESS POTENTIAL

Subject to terms & conditions negotiated with Kelly Scientific Publications prior to sale

Contents

1.0 EXECUTIVE SUMMARY

1.1 Objectives of Report

1.2 Data Sources & Methodology

1.3 Key Findings & Observations

1.3.1 The Global Drug Delivery Market has a Growth Rate of 5%

1.3.2 The Transdermal Drug Delivery Market is Growing Vertically

1.3.3 Who are the Leading Players in the Market?

1.3.4 Neurodegenerative Disorders Such as Alzheimer's and Parkinson's Disease Will Propel the Future Market

1.3.5 Why is the Transdermal Drug Delivery Market so Promising?

1.3.6 What are the Main Drivers of the Market?

1.3.7 First, Second and Third Generation Drug Delivery Systems

1.3.8 The Niche Market of Commercially Available Skin Models

1.3.9 Transdermal Drug Delivery Technologies are Providing the Market with Niche Spaces

1.3.10 Nanotechnology is Transforming Transdermal Drug Delivery

1.3.11 Can Transdermal Drug Delivery be Applied to Cancer Vaccination?

1.3.12 Gene Therapy Advancement Using Transdermal Delivery

2.0 TRANSDERMAL DRUG DELIVERY

2.1 Introduction

2.2 Developments of Transdermal Drug Delivery to Date

2.3 The Skin – Anatomy and Physiology

2.3.1 Drug Administration via the Intracellular Pathway

2.3.2 Drug Administration via the Intercellular Pathway

2.3.3 Fick's Law

2.4 Factors that Influence Transdermal Drug Delivery

2.4.1 Parameters Influencing Skin Permeability

2.4.1.1 The Vehicle

2.4.1.2 Drug Concentration

2.4.1.3 Partition Coefficient

2.5 Strategies to Enhance Transdermal Drug Delivery

2.5.1 1st Generation Delivery Systems

2.5.2 2nd Generation Delivery Systems

2.5.3 Chemical Enhancers

- 2.5.4 3rd Generation Delivery Systems
- 2.6 Comparison of Transdermal Delivery with Other Methods
- 2.7 Advantages of Transdermal Drug Delivery
 - 2.7.1 First-Pass Metabolism
- 2.8 Disadvantages of Transdermal Delivery
- 2.9 Complications of Transdermal Therapy
 - 2.9.1 Overdose
 - 2.9.2 Skin Sensitivity and Reactions
 - 2.9.3 MRI-Induced Skin Burns

3.0 BIOMECHANICAL AND PHARMACOLOGICAL ELEMENTS EFFECTING TRANSDERMAL DRUG DELIVERY

- 3.1 Factors That Influence Transdermal Drug Delivery
 - 3.1.1 Rate of Permeation Across the Skin
 - 3.1.2 Skin Characteristics
 - 3.1.3 Drug Characteristics
 - 3.1.4 pH and Pharmacokinetics
- 3.2 Transdermal Drug Design
 - 3.2.1 Factors That Affect the Absorption of the Drug
 - 3.2.1.1 Hydration and Temperature
 - 3.2.1.2 Biotransformation of the Drug in the Skin
 - 3.2.2 Selecting Drug and Vehicle
 - 3.2.3 Drug Modification
 - 3.2.3.2 Ion-Pair Formation
 - 3.2.3.3 Drug Complexation
 - 3.2.4 Thermodynamic Activity of the Drug within the Vehicle
 - 3.2.4.1 Eutectic Systems
 - 3.2.4.2 Vehicle Formulation
 - 3.2.4.3 Modification of the Stratum Corneum
- 3.3.1 Static Franz Diffusion Cell
- 3.4 Commercially Available Skin Models for Transdermal Drug Testing
- 3.5 In vivo Testing of Transdermal Drug Delivery Systems
 - 3.5.1 In vivo Testing of Drug Delivery Systems
 - 3.5.2 Modelling of Transport Through the Skin

4.0 TRANSDERMAL DRUG DELIVERY TECHNOLOGIES

- 4.1 Introduction

- 4.1.1 Local Application Formulations
- 4.1.2 Liquid Crystals for Transdermal Drug Delivery
- 4.1.3 Microemulsions for Transdermal Drug Delivery
- 4.1.4 Nanoemulsions for Transdermal Drug Delivery
- 4.1.5 Transdermal Gel Technology
- 4.1.6 Biphasic System
- 4.1.7 Penetration Enhancers
- 4.1.8 Chemical Enhancers
- 4.1.9 Nitric Oxide-Based Transdermal Drug Delivery
- 4.2 Vesicular transdermal carriers
 - 4.2.1 Liposomes
 - 4.2.2 Transfersomes
 - 4.2.3 Ethosomes
 - 4.2.4 Elastic Vesicles
- 4.3 Transdermal Patch
 - 4.3.1 Types of Transdermal Patch
 - 4.3.1a Single-layer Drug-in-Adhesive
 - 4.3.1b Multi-layer Drug-in-Adhesive
 - 4.3.1c Reservoir
 - 4.3.1d Matrix Patch
 - 4.3.1e Vapour Patch
 - 4.3.1 Transdermal Patches Adhesives
 - 4.3.2 New Technologies
 - 4.3.3 h-Patch Controlled Release Micropump System
- 4.4 Patchless Transdermal Delivery System
- 4.5 Metered-Dose Transdermal System
- 4.6 Polymers for Transdermal Drug Delivery
 - 4.6.2 Film Forming Polymeric Solutions
- 4.7 Physical Methods to Promote Transdermal Delivery
 - 4.7.1 Electrotransport
 - 4.7.2 Electroporation
 - 4.7.2.1 Drug delivery by Electroporation
 - 4.7.2.2 Electrochemotherapy
 - 4.7.3 Cryoelectrophoresis
 - 4.7.4 Iontophoresis
 - 4.7.4.1 Application of Iontophoresis for Drug Delivery
 - 4.7.4.2 Companies with Technologies for Drug Delivery by Iontophoresis
- 4.8 How Combining Electrophoresis and Iontophoresis Impacts Drug Delivery
- 4.9 Dermaportation

- 4.9.1 Radiofrequency-Driven Transdermal Delivery
- 4.9.2 Transcutaneous Drug Delivery by Electropulsation
- 4.9.3 Skin Patch Systems and Electrostatic Force
- 4.9.4 Heat-Aided Drug Delivery
- 4.9.5 Ultrasound
- 4.9.6 Magnetophoresis
- 4.10 Use of Lasers for Transdermal Drug Delivery
 - 4.10.1 Laser-Induced Microporation
 - 4.10.2 Painless Laser Injection
 - 4.10.3 Laser-Induced Pressure Waves
 - 4.10.3.1 Transdermal Drug Delivery by Laser-Assisted Changes in Skin
- 4.11 How Pressurized Gas is Transforming Transdermal Drug Delivery
- 4.12 Microscission Induced by Gas
- 4.13 Role of Microelectromechanical Systems (MEMS) in Transdermal Drug Delivery
- 4.14 Microneedles and Dermal Microinjection
- 4.15 Microneedle Arrays for Drug Delivery
 - 4.15.1 Microneedle Patch
 - 4.15.2 Applications of Microneedles
 - 4.15.3 AdminPatch Microneedle Array
 - 4.15.4 Dissolving Microneedles
- 4.16 Biodegradable Microneedles
- 4.17 Ceramic Microneedle Arrays
- 4.18 Dissolvable Microneedle Patches
 - 4.18.1 MicorCor
 - 4.18.2 MicroPyramid
- 4.19 Microstructured Transdermal Systems
- 4.20 Microneedle Transdermal Chip
- 4.21 Microneedle Applicator Device
- 4.22 DebioJect Microneedle Technology
- 4.23 Silk Microneedles
- 4.24 Tattooing
- 4.25 ZP Patch Microprojections Technology
- 4.26 Other Microneedle Products Currently Available
- 4.27 Needlefree injections
- 4.28 Glide SDI Solid Dose Injector
- 4.29 Jet Injection
 - 4.29.1 Why is Needle-Free so Important?
 - 4.29.2 Mini-Ject Needlefree Delivery System
 - 4.29.3 PharmaJet Stratis

- 4.29.4 MicroJet for Painless Injections
- 4.29.5 Nanoliter-Volume Pulsed Microjets
- 4.30 SUMAVEL DosePro Needle-Less Injection
- 4.31 Skin Abrasion

5.0 HOW NANOTECHNOLOGY IS TRANSFORMING TRANSDERMAL DRUG DELIVERY

- 5.1 Overview
- 5.2 Nanotechnology-Based Transdermal Drug Delivery
 - 5.2.1 Nanobiotechnology for Transdermal Application
- 5.3 Nanoparticles and Nanoemulsions for Skin Disorders
- 5.4 Nanopatches
 - 5.4.1 Vaxxas Nanopatch Technology
 - 5.4.2 Effect of Mechanical Flexion on Penetration of Bucky Amino Acids Through the Skin
- 5.5 Inocyte Epidermal Drug Delivery System
- 5.6 Ionic Nanoparticle Technology
- 5.7 Solid Lipid Nanoparticles (SLN) Gels
- 5.8 siRNA- Nanoparticle Conjugates
- 5.9 Transdermal Nanoparticle Preparations for Systemic Effect
- 5.10 Micellar Nanoparticle Estradiol Emulsion (MNPEE)
- 5.11 Transferosomes
- 5.12 Nanocarriers
- 5.13 Nanotechnology for Vaccination and Immunotherapy
- 5.14 Safety Issues of Applications of Nanomaterial Carriers on the Skin
- 5.15 Comparison of Current Transdermal Drug Delivery Systems

6.0 TRANSDERMAL DRUG DELIVERY AND DISEASE STATES

- 6.1 Antiaging Products
- 6.2 Cancer
 - 6.2.1 γ -Amino Levulinic Acid
 - 6.2.2 Breast Cancer & Afimoxifene Gel
 - 6.2.3 Cervical Cancer & Interferon γ 2b
 - 6.2.4 Prostate Cancer & Nitroglycerine
 - 6.2.5 Prostate Cancer & Estradiol Gel
 - 6.2.6 Prostate Cancer & Leuprolide Acetate
 - 6.2.7 Skin Cancer & Caffeine

- 6.2.6 Cancer Vaccines
 - 6.2.6.1 Intradermal Delivery Using Adenoviral Vectors
 - 6.2.6.2 Peptide Cancer Vaccines
 - 6.2.6.3 Electroporation of Anticancer Agents
- 6.3 Cardiovascular Disease
 - 6.3.1 Transdermal Anticoagulants
 - 6.3.2 Angina Pectoris
 - 6.3.3 Atherosclerotic Cardiovascular Disease
 - 6.3.3.1 Transdermal Oestrogen for Prevention of Atherosclerotic Cardiovascular Disease
 - 6.3.4 Congestive Heart Failure
 - 6.3.5 Hypertension
 - 6.3.5.1 Clonidine
 - 6.3.5.2 β -Blockers
 - 6.3.5.3 Calcium Channel Blockers
- 6.4 Chronic Fatigue Syndrome
- 6.5 Contraception
 - 6.5.1 Female Contraception
 - 6.5.1.1 Agile Therapeutics AG200-15
 - 6.5.1.2 BAY86-5016 / FC Patch Low BAY86-5016
 - 6.5.1.3 Desogestrel
 - 6.5.1.4 Ortho Evra
 - 6.5.2 Male Contraception
 - 6.5.2.1 Transdermal Progestin Plus Testosterone
- 6.6 Diabetes
 - 6.6.1 Insulin Drug Delivery
 - 6.6.1.1 V-Go
 - 6.6.1.2 GLP1 Agonist
- 6.7 Men's Health
 - 6.7.1 Benign Prostatic Hypertrophy
 - 6.7.1.2 Tamsulosin Transdermal Drug Delivery System
 - 6.7.2 Erectile Dysfunction
 - 6.7.2.1 Topical and Transdermal Preparation for Erectile Dysfunction
 - 6.7.3 Hypogonadism
 - 6.7.3.1 Topical Testosterone
- 6.8 Musculoskeletal Disease
 - 6.8.1 Osteoarthritis
 - 6.8.2 Osteoporosis
 - 6.8.2.1 Alendronate

- 6.8.2.2 Estrogen
- 6.8.2.3 Human Parathyroid Hormone
- 6.9 Nausea and Vomiting
 - 6.9.1 Chemotherapy-Induced
 - 6.9.2 Motion Sickness
 - 6.9.3 Postoperative Vomiting
- 6.10 Neurological Disease
 - 6.10.1 Alzheimer's Disease
 - 6.10.1.1 Arecoline
 - 6.10.1.2 Rivastigmine
 - 6.10.1.3 Donepezil
- 6.11 Attention Deficit Hyperactivity Disorder
 - 6.11.1 Methylphenidate
- 6.12 Bipolar Disorder
 - 6.12.1 Lithium
- 6.13 Depression
 - 6.13.1 Antidepressants
 - 6.13.2 Selective Serotonin-Reuptake Inhibitors
 - 6.13.3 Fluoxetine
 - 6.13.4 Monoamine Oxidase Inhibitors
 - 6.13.5 Selegiline
 - 6.13.6 Trazodone Hydrochloride
 - 6.13.7 Venlafaxine
 - 6.13.8 Bupropion
- 6.14 Epilepsy
- 6.15 Migraine
 - 6.15.1 Sumatriptan
 - 6.15.2 Zolmitriptan
- 6.16 Parkinson's Disease
 - 6.16.1 Introduction
 - 6.16.2 Dopamine Agonists
 - 6.16.2.1 Levodopa
 - 6.16.2.2 Rotigotine
 - 6.16.3 Other Agents
- 6.17 Restless Leg Syndrome
 - 6.17.1 Rotigotine
- 6.18 Schizophrenia
 - 6.18.1 Haloperidol
 - 6.18.2 Risperidone

- 6.18.3 Blonanserin
- 6.19 Tinnitus/Vertigo
 - 6.22.1 Nicotine
- 6.20 Tourette syndrome
- 6.21 Multiple Sclerosis
- 6.22 Respiratory diseases
 - 6.22.1 Asthma and Chronic Obstructive Pulmonary Disease (COPD)
- 6.23 Skin disorders
 - 6.23.1 Cutaneous Leishmaniasis
 - 6.23.2 Hair Loss
 - 6.23.3 Iontophoretic Drug Delivery for Nail Disorders
 - 6.23.4 Psoriasis
 - 6.23.4.1 Nanoemulsions for Paxitacel in Psoriasis
 - 6.23.4.2 Iontophoresis for Treatment of Psoriasis
- 6.24 Overactive Bladder and Urinary Incontinence
 - 6.24.1 Oxybutynin
- 6.25 Pain
 - 6.25.1 Chronic Pain
 - 6.25.2 Transdermal Local Anesthetics
 - 6.25.3 Transdermal Fentanyl for the Management of Postoperative Pain
 - 6.25.4 Fibromyalgia
 - 6.25.5 Minor Medical Procedures
 - 6.25.6 Neuralgia
 - 6.25.6.1 Lidoderm
 - 6.25.7 Nonsteroidal Anti-Inflammatory Drugs
 - 6.25.7.1 Topical NSAIDs
 - 6.25.8 Ketoprofen
 - 6.25.9 Opioids
 - 6.25.10 Cancer Pain
 - 6.25.10.1 Fentanyl
 - 6.25.10.2 Nitroglycerine
 - 6.25.10.3 Buprenorphine
- 6.26 Smoking Cessation
 - 6.26.1 Nicotine Replacement Therapy
 - 6.26.2 Nicotine Patch in Pregnancy
- 6.27 Viral infections
 - 6.27.1 Transdermal Nanoparticles for Immune Enhancement in HIV
- 6.28 Women's Health
 - 6.28.1 Dysmenorrhea

- 6.28.2 Female Infertility
- 6.28.3 Female Sexual Arousal Disorder
- 6.28.4 Menopause
 - 6.28.4.1 Hormone Replacement Therapy
- 6.28.5.2 Estradiol
- 6.28.5.3 Parathyroid Hormone for Postmenopausal Osteoporosis
- 6.28.5.4 Testosterone and Low Libido
- 6.29 Transdermal Nutraceuticals

7.0 GENE THERAPY AND TRANSDERMAL DRUG DELIVERY

- 7.1 Overview
- 7.2 Plasmid DNA and Electroporation
 - 7.2.1 TriGrid Delivery System
 - 7.2.2 CELLECTRA
 - 7.2.3 Magnetic Pulse Electroporation
- 7.3 Antisense Therapy

8.0 VACCINES AND TRANSDERMAL DRUG TECHNOLOGY

- 8.1 Introduction
 - 8.1.1 The Skin as an Immune Organ
 - 8.1.1.1 Langerhans Cells- Epidermal Antigen Presenting Cells
 - 8.1.1.2 Keratinocytes- Immune Competent Epithelial cells
 - 8.1.1.3 Dendritic Epidermal T Cells (DETC) ?? T cells -Specialised Resident Epithelial Cells
 - 8.1.1.4 Epidermotropic T lymphocytes-Circulating T Cells that home to the Epidermis
 - 8.1.1.5 Melanocytes-Epidermal Pigment Cells With Immune Properties
- 8.2 Current Technologies
 - 8.2.1 Dissolvable Microneedle Array
 - 8.2.2 Electroporation for Administering DNA Vaccines
 - 8.2.3 Microneedles for Transdermal Vaccine Delivery
 - 8.2.4 Needle-Free Delivery of Vaccines
- 8.3 Applications for Transdermal Vaccination
 - 8.3.1 HIV/AIDS Vaccine
 - 8.3.2 Transdermal DNA Influenza Vaccine
 - 8.3.3 Transdermal A? Vaccine for Alzheimer's Disease
 - 8.3.4 Transdermal Vaccine for Traveller's Diarrhoea

9.0 GLOBAL DRUG DELIVERY MARKET

- 9.1 Overview and Analysis
- 9.2 USA Drug Delivery Market
- 9.3 European Drug Delivery Market
- 9.4 Emerging Drug Delivery Markets
- 9.5 The Advanced Drug Delivery Landscape
- 9.6 Transdermal Drug Delivery Market
- 9.7 Smoking Cessation Drug Market
 - 9.7.1 Nicotine Replacement Therapeutics
 - 9.7.2 Non-Nicotine Containing Therapeutics
 - 9.7.3 Smoking Cessation Products in the Pipeline
- 9.8 Neurodegenerative Disorders Such as Alzheimer's & Parkinson's disease will Propel the Future Market
- 9.9 How Transdermal Systems Relate to the Global Pain Market
 - 9.9.1 Neuropathic Pain Market (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020
 - 9.9.2 Transdermal Products Within the Neuropathic Pain Market
- 9.10 How Transdermal Systems Relate Within the Generic Market
- 9.11 Duragesic and Generic Fentanyl Transdermal System Competition
- 9.12 Lidocaine Market Analysis
- 9.13 Who are the Leading Players in the Market?
- 9.14 What is Driving the Transdermal Drug Delivery Market?
- 9.15 Increased Number of Geriatric and Pediatric Patients is Propelling the Market
- 9.16 Unmet Needs Within the Transdermal Drug Delivery Market
- 9.17 Women's Health Market

10.0 TRANSDERMAL DRUG DELIVERY COMPANY BUSINESS PROFILES AND STRATEGIC EVALUATION

- 10.1 Actavis
- 10.2 Actelion
- 10.3 GlaxoSmithKline
- 10.4 Bayer
- 10.5 Mylan Pharmaceuticals
- 10.6 Novartis
- 10.7 Upsher-Smith
- 10.8 Ascend Therapeutics
- 10.9 AMAG Pharmaceuticals (Lumara Health, KV Pharma/Ther-Rx Corp)

- 10.10 Janssen Pharmaceuticals
- 10.11 Noven Pharmaceuticals
- 10.12 ProStrakan
- 10.13 Shire
- 10.14 Hercon Pharmaceutical
- 10.15 Kremers Urban Pharmaceuticals
- 10.16 Nitto Denko
- 10.17 Teva Pharmaceutical Industries
- 10.18 Endo International
- 10.19 Teikoku USA
- 10.20 Boehringer Ingelheim
- 10.21 3M
- 10.22 UCB
- 10.23 ParPharm

11.0 TRANSDERMAL DRUG DELIVERY COMPANY FINANCIAL ANALYSIS

- 11.1 Actavis
- 11.2 Actelion
- 11.3 GlaxoSmithKline
 - 11.3.1 ViiV Healthcare
- 11.4 Bayer
- 11.5 Janssen Pharmaceuticals (Johnson & Johnson)
- 11.6 Shire
- 11.7 Nitto Dento
- 11.8 Teva Pharmaceuticals
- 11.9 Endo International
- 11.10 Boehringer Ingelheim
- 11.11 3M
- 11.12 UCB
- 11.13 ParPharm

12.0 CURRENT TRANSDERMAL DRUG DELIVERY PRODUCTS ON THE MARKET

- 12.1 Actavis
 - 12.1.1 Androderm
 - 12.1.2 Fentanyl Transdermal System
 - 12.1.3 Lidocaine Topical Patch
 - 12.1.4 Oxytrol

12.2 Actelion

12.2.1 Vachlor Gel (mechlorethamine)

12.3 GlaxoSmithKline

12.3.1 Niquitin/Nicoderm

12.4 Bayer

12.5 Mylan Pharmaceuticals

12.5.1 Clonidine Transdermal System

12.5.2 EMSAM (Selegiline Transdermal System)

12.5.3 Estradiol Transdermal System

12.5.4 Fentanyl Transdermal System

12.5.5 Nitroglycerin Transdermal System

12.5.6 XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System)

12.6 Novartis

12.6.1 Exelon Patch (Rivastigmine Transdermal System)

12.6.2 Duragesic - Fentanyl Patches

12.6.3 Transderm Scop - Scopolamine Patches

12.7 Upsher-Smith

12.7.1 Vogelxo – Testosterone (1%) Gel

12.8 ASCEND Therapeutics

12.8.1 EstroGel

12.9 AMAG Pharmaceuticals (Lumara Health)

12.9.1 Evamist

12.10.1 OrthoEvra

12.10.2 Duragesic

12.11 Lavipharm

12.11.1 Fentadur

12.11.2 Nicotine Transdermal Patch

12.11.3 Acne Transdermal Patch

12.11.4 Trinipatch

12.12 Noven Pharmaceuticals

12.12.1 Minivelle

12.12.2 CombiPatch

12.12.3 Daytrana

12.13 ProStraken

12.13.1 Sancuso

12.14 Shire

12.14.1 Daytrana CII

12.15 Hercon Pharmaceuticals

12.15.1 Nitroglycerin Transdermal System

- 12.16 Kremers Urban Pharmaceuticals
 - 12.16.1 Nitroglycerin Transdermal System
- 12.17 Nitto Dento
 - 12.17.1 Biso Tapes
 - 12.17.2 Penles Tapes
 - 12.17.3 Passport Advanced Drug Delivery System
- 12.18 Teva Pharmaceuticals
 - 12.18.1 Zecuity
 - 12.18.2 Transdermal Fentanyl (generic)
 - 12.18.3 Tev Tropin
- 12.19 Endo International
 - 12.19.1 Lidoderm Patch
 - 12.19.2 Fortesa Gel
- 12.20 Teikoku
 - 12.20.1 Lidoderm
 - 12.20.2 Ionto Patch
- 12.21 3M
 - 12.21.1 3M Fentanyl Transdermal Delivery System
 - 12.21.2 3M Rivastigmine Transdermal Delivery System
 - 12.21.3 Microneedles
- 12.22 UCB
 - 12.22.1 Neupro
- 12.23 ParPharm
 - 12.23.1 Fentanyl Transdermal System

13.0 IN-DEPTH SWOT ANALYSIS OF THE TRANSDERMAL DRUG DELIVERY MARKET

- 13.1 Drivers of the Market
 - 13.1.1 Patent Expirations and Introduction of Generics
 - 13.1.2 Increased Patient Compliance Rates
 - 13.1.3 Increased Rate of Chronic Conditions and Application of Patch Technology to These Areas
 - 13.1.4 Increased Geriatric and Pediatric Drug Administration Requirements
- 13.2 Restraints and Weaknesses of the Transdermal Drug Delivery Market
 - 13.2.1 Technical Restraints
 - 13.2.2 Drug Adverse Reactions
 - 13.2.3 Drug Failures
- 13.3 Opportunities Within the Market Place

- 13.3.1 High number of Pharmaco & Drug Delivery Company Collaboration
- 13.3.2 Increasing Indications and Disease States for Transdermal Administration
- 13.3.3 Large Opportunity for Home Health Care Market and OTC
- 13.3.4 Targeted Drug Delivery
- 13.4 Barriers to Market Entry

COMPANIES MENTIONED

Actavis
Actelion
GlaxoSmithKline
Bayer
Mylan Pharmaceuticals
Novartis
Upsher-Smith
Ascend Therapeutics
AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp)
Janssen Pharmaceuticals
Noven Pharmaceuticals
ProStrakan
Shire
Hercon Pharmaceutical
Kremers Urban Pharmaceuticals
Nitto Denko
Teva Pharmaceutical Industries
Endo International
Teikoku USA
Boehringer Ingelheim
3M
UCB
ParPharm

About

This comprehensive report tackles problems that this vertical growing market faces and evaluates saturated sub-markets. A detailed outlay of its major players is performed including business strategy and future development analysis, merger and acquisition tactics, current product and pipeline entry evaluation and a detailed section on each player's financial situation.

This analysis determines the unmet needs of the transdermal drug delivery industry and specific niche areas of market entry. The transdermal drug delivery market has substantial associations within the smoking cessation market, analgesics/pain market, generics market, neuropathic pain market and also the women's health market. In the future it will significantly enter the vaccine and gene therapy markets. Transdermal drug delivery is a complex area that has many driving factors including the unmet need for non-invasive drug delivery systems for pediatric, geriatric and dementia patients.

This report describes the current technologies that are propelling the market space and emerging trials and pipeline agents that will make a significant impact on the industry. It examines the current transdermal delivery systems and how generic competition is allowing penetration of new players in the market and saturation of niche areas.

Financial figures of the drug delivery market and the transdermal drug delivery space are revealed in this report. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the transdermal drug delivery industry.

Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the transdermal drug delivery market has huge opportunities for growth in the areas of dementia (Alzheimer's & Parkinson's Disease), generics, paediatrics and geriatrics. Currently the USA is the most prominent market place, followed by Europe, Asia and Emerging Markets. This report will reveal in-depth analysis of the industry and provide cutting-edge intelligence on the current and future spaces it will penetrate.

I would like to order

Product name: Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation'

Product link: <https://marketpublishers.com/r/G646DE368B1EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G646DE368B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970